Biomarkers in clinical trials: Can we move from fortune telling to disease profiling?

Circulation

Volumn 124, Issue 6, 2011, Pages 663-665

  De Lemos, James A ^a   McGuire, Darren K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; FIBRINOPEPTIDE A; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SIDE EFFECT;

BIOLOGICAL MARKERS; BLOOD PROTEINS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; PHENOTYPE; PROGNOSIS; RISK ASSESSMENT;

EID: 80051737053     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.044271     Document Type: Review

References (12)

1. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-2416.
2. Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD III, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL; for the BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2011;124:695-703.
3. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666-675. (Pubitemid 40239214)
4. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E. A sensitive cardiac troponin t assay in stable coronary artery disease. N Engl J Med. 2009;361:2538-2547.
5. Eggers KM, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Jantzen F, Peter T, Allhoff T, Siegbahn A, Venge P, Wollert KC, Wallentin L. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet. 2010;3:88-96.
6. McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus, part I: thiazolidinediones and their evolving cardiovascular implications. Circulation. 2008;117:440-449.
7. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U. S. Food and Drug Administration. N Engl J Med. 2010;363:1489-1491.
8. McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, Ayers CR, Drazner MH, Khera A, de Lemos JA. Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur Heart J. 2010;31:2262-2270.
9. Albu JB, Lu J, Mooradian AD, Krone RJ, Nesto RW, Porter MH, Rana JS, Rogers WJ, Sobel BE, Gottlieb SH. Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Obesity (Silver Spring). 2010;18:1046-1054.
10. Gore MO, McGuire DK. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. Curr Cardiol Rep. 2009;11:258-263.
11. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
12. US Department of Health and Human Services. NIH stops clinical trial on combination cholesterol treatment. http://public. Nhlbi. Nih. Gov/newsroom/home/getpressrelease. Aspx?Id=2792. Accessed June 4, 2011.